BibTex format
@article{Thompson:2022:10.1016/S2214-109X(22)00416-8,
author = {Thompson, HA and Hogan, AB and Walker, PGT and Winskill, P and Zongo, I and Sagara, I and Tinto, H and Ouedraogo, J-B and Dicko, A and Chandramohan, D and Greenwood, B and Cairns, M and Ghani, AC},
doi = {10.1016/S2214-109X(22)00416-8},
journal = {The Lancet Global Health},
pages = {e1782--e1792},
title = {Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study},
url = {http://dx.doi.org/10.1016/S2214-109X(22)00416-8},
volume = {10},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: A 2021 clinical trial of seasonal RTS,S/AS01E (RTS,S) vaccination showed that vaccination was non-inferior to seasonal malaria chemoprevention (SMC) in preventing clinical malaria. The combination of these two interventions provided significant additional protection against clinical and severe malaria outcomes. Projections of the effect of this novel approach to RTS,S vaccination in seasonal transmission settings for extended timeframes and across a range of epidemiological settings are needed to inform policy recommendations. METHODS: We used a mathematical, individual-based model of malaria transmission that was fitted to data on the relationship between entomological inoculation rate and parasite prevalence, clinical disease, severe disease, and deaths from multiple sites across Africa. The model was validated with results from a phase 3b trial assessing the effect of SV-RTS,S in Mali and Burkina Faso. We developed three intervention efficacy models with varying degrees and durations of protection for our population-level modelling analysis to assess the potential effect of an RTS,S vaccination schedule based on age (doses were delivered to children aged 6 months, 7·5 months, and 9 months for the first three doses, and at 27 months of age for the fourth dose) or season (children aged 5-17 months at the time of first vaccination received the first three doses in the 3 months preceding the transmission season, with any subsequent doses up to five doses delivered annually) in seasonal transmission settings both in the absence and presence of SMC with sulfadoxine-pyrimethamine plus amodiaquine. This is modelled as a full therapeutic course delivered every month for four or five months of the peak in transmission season. Estimates of cases and deaths averted in a population of 100000 children aged 0-5 years were calculated over a 15-year time period for a range of levels of malaria transmission intensity (Plasmodium falciparum parasite prevalence i
AU - Thompson,HA
AU - Hogan,AB
AU - Walker,PGT
AU - Winskill,P
AU - Zongo,I
AU - Sagara,I
AU - Tinto,H
AU - Ouedraogo,J-B
AU - Dicko,A
AU - Chandramohan,D
AU - Greenwood,B
AU - Cairns,M
AU - Ghani,AC
DO - 10.1016/S2214-109X(22)00416-8
EP - 1792
PY - 2022///
SN - 2214-109X
SP - 1782
TI - Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
T2 - The Lancet Global Health
UR - http://dx.doi.org/10.1016/S2214-109X(22)00416-8
UR - https://www.ncbi.nlm.nih.gov/pubmed/36400084
UR - http://hdl.handle.net/10044/1/100655
VL - 10
ER -
